leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PRESS RELEASE

...see all

Checkpoint Inhibitor For Treating Cancer Market Set To Grow To Over $7.6bn In 2017

LONDON, UK. 25th October 2017: Visiongain has launched a new pharma report Checkpoint Inhibitors for Treating Cancer Market Report 2017-2027: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs.

Checkpoint inhibitors are significant because they utilise the greatest tool that the body has to fight cancer- its own immune defence system. Checkpoint inhibitors are agents that block immune checkpoints on lymphocytes so that immune activity is not down-regulated and continues against cancerous cells. This inhibition can enhance T-cell activity by not only allowing them to remain active but can modulate different types of immune defence system cells such as CD4 T-cells, CD8 T-cells or NK (natural killer) cells.

The potential that the immune system has cannot be overstated and if was harnessed properly, it could be used to wipe out cancer cells from the body completely and in theory result in fewer side effects. The immune defence system in the body has countless cellular interactions that can work against cancerous cells and has the ability to detect even a few tumour cells, conduct surveillance of them, and retain a memory of them which ensures long-term effects.

The lead Visiongain report analyst for this report commented; “The checkpoint inhibitor anti-cancer treatment market has gotten off the ground only in the last few years, but it is expected to continue to rise and change the landscape of cancer treatment. This market has already made strides in melanoma and NSCLC (non-small cell lung cancer) treatment, which have not had this much progress in more than ten years. This trend will continue with further approvals for novel treatments that can offer something new owing to their mechanisms - namely long-term duration of effects. Checkpoint inhibitors utilise the vast potential of the body’s own immune response system and its countless connections to attack cancer cells in the body and use the immune memory cells to eliminate relapses. A recurrence of cancer cells in the body could be recognised and wiped out using this method and could leave healthy tissue alone, curbing side effects and increasing the patient benefit-risk ratio. With this kind of potential, many companies have invested in development of checkpoint inhibitors and the pipeline for these treatments is robust and has a promising future.”

The Checkpoint Inhibitor for Treating Cancer market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the global next generation sequencing market Bristol-Myers Squibb and Merck & Co, the first two companies to obtain marketing authority for their PD-1 and CLTA-4 Inhibitors for the purpose of treating cancer.

 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.
 

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

read more

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close